Barish Ozdamar, PhD

Federal Circuit Opinion On Patent Eligibility Of Machine Learning Applications Underscores Potential Value Of Trade Secrecy To Protecting AI Innovation

Amgen Hasn't Resolved Questions On AI Medical Invention Patents

Recent FDA Guidance Addressing Platform Technologies

Disclosure Of Antibody's Equivalents Not Necessary To Satisfy Written Description And Indefiniteness Requirements For A Means-Plus-Function Claim Term

Recent Appellate Decision Overturns Revocations Of Broad Institute CRISPR-Cas9 Patents

Recent Decision Raises Patent Eligibility Concerns Regarding Certain Gene Therapy-Related Inventions